Recruiting CIML NK Cells With Venetoclax for AML NCT06152809 Conditions Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Hematologic Diseases, +6 more Locations Brigham and Women's Hospital — Boston, Massachusetts, United States Dana-Farber Cancer Institute — Boston, Massachusetts, United States View Trial Details
Recruiting CLAG-GO for Patients With Persistent, Relapsed or Refractory AML NCT04050280 Conditions Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia, Relapsed, Adult, +11 more Locations University of Maryland Greenebaumn Comprehensive Cancer Center — Baltimore, Maryland, United States View Trial Details
Recruiting A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184 Conditions AML With Mutated NPM1, Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, +19 more Locations Mayo Clinic - Phoenix — Phoenix, Arizona, United States Moores UC San Diego Cancer Center — La Jolla, California, United States USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States UCLA - Bowyer Oncology Center — Los Angeles, California, United States View all 44 locations View more locations Show fewer locations Loading locations... View Trial Details
